Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
The expression of Ki67, BCL-2, and COX-2 was investigated in 53 canine cutaneous mast cell tumors (MCTs) by immunohistochemistry and quantitative real time polymerase chain reaction (qPCR) to evaluate their prognostic significance and the association with the histologic grading and the mitotic index (MI). MCTs were graded according to the Patnaik grading system and the novel 2-tier grading system proposed by Kiupel. The numbers of mitotic figures/10 high-power fields (MI) were counted. Both grading systems were significantly associated with prognosis. The Patnaik grading was of limited prognostic value for grade 2 MCTs, with 23% being associated with mortality. The concordance among pathologists was strongly improved by the application of the 2-tier grading system, and 71% of high-grade MCTs were associated with a high mortality rate. MI and Ki67 protein expression were significantly associated with grading and survival. No significant association between BCL-2 protein expression and either grading system or health status was observed. BCL-2 mRNA expression was significantly higher in grade 2 than in grade 1 MCTs, while no statistically significant differences were detected between low- and high-grade MCTs. The increased BCL-2 mRNA level was significantly associated with increased mortality rate. The COX-2 protein expression was detected in 78% of the MCTs investigated. However, neither association with the tumor grade nor with the health status was observed. COX-2 mRNA was significantly up-regulated in MCTs compared to surgical margins and control skin tissue, but it was neither associated with tumor grade nor with survival.
Istituto Zooprofilattico Sperimentale delle Venezie, Italy. mvascellari@izsvenezie.it
M
M
Vascellari
M
M
Giantin
K
K
Capello
A
A
Carminato
E M
EM
Morello
A
A
Vercelli
A
A
Granato
P
P
Buracco
M
M
Dacasto
F
F
Mutinelli
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D004283:Dog Diseases / Q000378:metabolism / Q000473:pathology*; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D007150:Immunohistochemistry / Q000662:veterinary; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D008297:Male; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology; D012515:Mast-Cell Sarcoma / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D034701:Mastocytosis, Cutaneous / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D008940:Mitotic Index; D060787:Neoplasm Grading / Q000662:veterinary; D011379:Prognosis; D011446:Prospective Studies; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D012867:Skin / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D051546:Cyclooxygenase 2